Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2009 2
2010 1
2011 2
2012 1
2013 5
2014 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T, Kidokoro H, Harimoto H, Fukuda T, Matsushita Y, Nakatsuka K, Sakamoto C. Narahara Y, et al. Among authors: kidokoro h. J Gastroenterol Hepatol. 2009 Nov;24(11):1791-7. doi: 10.1111/j.1440-1746.2009.05873.x. Epub 2009 Aug 3. J Gastroenterol Hepatol. 2009. PMID: 19686420 Clinical Trial.
Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study.
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Atsukawa M, et al. Among authors: kidokoro h. Hepat Mon. 2013 Dec 23;13(12):e14872. doi: 10.5812/hepatmon.14872. eCollection 2013. Hepat Mon. 2013. PMID: 24403915 Free PMC article.
Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.
Atsukawa M, Tsubota A, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Kanazawa H, Sakamoto C. Atsukawa M, et al. Among authors: kidokoro h. J Gastroenterol Hepatol. 2013 Jan;28(1):51-6. doi: 10.1111/j.1440-1746.2012.07267.x. J Gastroenterol Hepatol. 2013. PMID: 22989264 Clinical Trial.
Effects of transjugular intrahepatic portosystemic shunt on changes in the small bowel mucosa of cirrhotic patients with portal hypertension.
Matsushita Y, Narahara Y, Fujimori S, Kanazawa H, Itokawa N, Fukuda T, Takahashi Y, Kondo C, Kidokoro H, Atsukawa M, Nakatsuka K, Sakamoto C. Matsushita Y, et al. Among authors: kidokoro h. J Gastroenterol. 2013 May;48(5):633-9. doi: 10.1007/s00535-012-0660-6. Epub 2012 Sep 13. J Gastroenterol. 2013. PMID: 22968470
Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C. Itokawa N, et al. Among authors: kidokoro h. J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039. J Gastroenterol Hepatol. 2013. PMID: 23173698 Clinical Trial.
Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.
Narahara Y, Kanazawa H, Fukuda T, Matsushita Y, Harimoto H, Kidokoro H, Katakura T, Atsukawa M, Taki Y, Kimura Y, Nakatsuka K, Sakamoto C. Narahara Y, et al. Among authors: kidokoro h. J Gastroenterol. 2011 Jan;46(1):78-85. doi: 10.1007/s00535-010-0282-9. Epub 2010 Jul 15. J Gastroenterol. 2011. PMID: 20632194 Clinical Trial.
11 results